Nelemans PJ - Search Results

1

Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis.

Mostard RL, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Vöö S, Drent M. Mostard RL, et al. Among authors: nelemans pj. Respir Med. 2013 Mar;107(3):439-47. doi: 10.1016/j.rmed.2012.11.011. Epub 2012 Dec 19. Respir Med. 2013. PMID: 23261309 Free article.

2

Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in the Netherlands.

Wijnen PA, Drent M, Nelemans PJ, Kuijpers PM, Koek GH, Neef C, Haenen GR, Bekers O. Wijnen PA, et al. Among authors: nelemans pj. Drug Saf. 2008;31(12):1125-34. doi: 10.2165/0002018-200831120-00008. Drug Saf. 2008. PMID: 19026029

3

The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis.

Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. Wijnen PA, et al. Among authors: nelemans pj. Tissue Antigens. 2010 Mar;75(3):262-8. doi: 10.1111/j.1399-0039.2009.01437.x. Epub 2010 Jan 11. Tissue Antigens. 2010. PMID: 20070603

4

Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment.

Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Elfferich MD, et al. Among authors: nelemans pj. Respiration. 2010;80(3):212-9. doi: 10.1159/000314225. Epub 2010 Apr 29. Respiration. 2010. PMID: 20431280 Free article.

5

Butyrophilin-like 2 in pulmonary sarcoidosis: a factor for susceptibility and progression?

Wijnen PA, Voorter CE, Nelemans PJ, Verschakelen JA, Bekers O, Drent M. Wijnen PA, et al. Among authors: nelemans pj. Hum Immunol. 2011 Apr;72(4):342-7. doi: 10.1016/j.humimm.2011.01.011. Epub 2011 Jan 20. Hum Immunol. 2011. PMID: 21256912

6

Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.

Mostard RL, Vöö S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M. Mostard RL, et al. Among authors: nelemans pj. Respir Med. 2011 Dec;105(12):1917-24. doi: 10.1016/j.rmed.2011.08.012. Epub 2011 Sep 6. Respir Med. 2011. PMID: 21899998 Free article.

7

A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis.

Mostard RL, Van Kuijk SM, Verschakelen JA, van Kroonenburgh MJ, Nelemans PJ, Wijnen PA, Drent M. Mostard RL, et al. Among authors: nelemans pj. BMC Pulm Med. 2012 Sep 14;12:57. doi: 10.1186/1471-2466-12-57. BMC Pulm Med. 2012. PMID: 22978780 Free PMC article.

8

Body composition profiling in a Dutch sarcoidosis population.

Cremers JP, Drent M, Elfferich MD, Nelemans PJ, Wijnen PA, Witteman BJ, Schols AM. Cremers JP, et al. Among authors: nelemans pj. Sarcoidosis Vasc Diffuse Lung Dis. 2013 Dec 17;30(4):289-99. Sarcoidosis Vasc Diffuse Lung Dis. 2013. PMID: 24351620

9

Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis.

Wijnen PA, Cremers JP, Nelemans PJ, Erckens RJ, Hoitsma E, Jansen TL, Bekers O, Drent M. Wijnen PA, et al. Among authors: nelemans pj. Eur Respir J. 2014 Jun;43(6):1730-9. doi: 10.1183/09031936.00169413. Epub 2014 Feb 20. Eur Respir J. 2014. PMID: 24558177 Free article.

10

Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1.

Brinkman M, Jentjens S, Boone K, Anten M, Stumpel CTRM, Nelemans PJ, van Kroonenburgh MJPG. Brinkman M, et al. Among authors: nelemans pj. Nucl Med Commun. 2018 Nov;39(11):961-968. doi: 10.1097/MNM.0000000000000889. Nucl Med Commun. 2018. PMID: 30106798 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

264 results

Search Page

Filters